| Author | Country | Cancer type | Clinical stage | Sample size | Cut off value | Follow up (months) | Detection method | Adjuvant therapy | Survival analysis | Outcome measure | NOS |
| Cedric, 2020 | China | HCC | T1 - T4 | 62 | Mean | - | qRT-PCR | None | Univariate | CP | 7 |
| Li, 2021 | China | HCC | I-III | 49 | NA | - | qRT-PCR | None | Univariate | CP | 7 |
| Lin, 2021 | China | HCC | I-IV | 50 | Median | 60 | qRT-PCR | None | Multivariate | OS, CP | 9 |
| Tan, 2019 | China | HCC | - | 80 | Mean | 60 | qRT-PCR | None | Univariate | OS | 8 |
| Xu, 2021 | China | HCC | I-IV | 40 | NA | - | qRT-PCR | None | Univariate | CP | 7 |
| Yang, 2019 | China | HCC | I-IV | 30 | Median | - | qRT-PCR | None | Univariate | CP | 7 |
| Zhan, 2020 | China | HCC | I-IV | 60 | NA | 100 | qRT-PCR | None | Univariate | OS, CP | 9 |
| Fang, 2020 | China | ESCC | I-IV | 58 | Median | - | qRT-PCR | None | Univariate | CP | 7 |
| Huang, 2020 | China | GC | - | 60 | NA | 60 | qRT-PCR | None | Univariate | OS | 8 |
| Zhang, 2017 | China | CRC | I-IV | 170 | NA | - | qRT-PCR | None | Univariate | CP | 7 |